According to a press release, diabetes drug company Daiichi Sankyo Inc. today announced that the US FDA (Food and Drug Administration) have granted approval for diabetes drug Welchol. The type 2 diabetes drug is hailed as a unique pioneer drug that reduces both forms of cholesterol .
Welchol has been created following statistics that some 40 per cent of type 2 diabetics also suffer from high LDL cholesterol . Welchol plugs a gap in the market, apparently allowing patients to treat both health conditions at the same time.
Welchol has been through several phases of clinical trials, and its efficacy was highlighted during a presentation at the ADA (American Diabetes Association) Scientific Sessions in Chicago last year.
One diabetes expert, Ronald Goldberg MD, was reported as commenting: “Welchol now offers physicians a treatment option that addresses two major cardiovascular risk factors; elevated LDL cholesterol and blood glucose in patients with type 2 diabetes. Cardiovascular risk factors are of great concern because patients with type 2 diabetes have a significantly increased risk of developing cardiovascular disease . Once clinical cardiovascular disease develops, these patients have a poorer prognosis than normoglycemic patients.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…